alexa Toward Precision Therapy in ANCA-Associated Vasculitides: More Transcriptomic Data is Needed in the Quest for Reliable Biomarkers | OMICS International
ISSN: 2471-9544
Journal of Vasculitis

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Toward Precision Therapy in ANCA-Associated Vasculitides: More Transcriptomic Data is Needed in the Quest for Reliable Biomarkers

Jourde-Chiche Noémie1,2* and Laurent Chiche3

1Aix-Marseille University, Department of Nephrology, AP-HM Hopital de la Conception, Marseille, France

2Aix-Marseille University, Vascular Research Center of Marseille, Marseille, France

3Hopital Europeen, Department of Internal Medicine, Marseille, France

*Corresponding Author:
Jourde-Chiche Noemie
Aix-Marseille University
Department of Nephrology
AP-HM Hopital de la Conception, Marseille, France
Tel: 330491383042
E-mail: [email protected]

Received date: September 01, 2015; Accepted date: September 03, 2015; Published date: September 06, 2015

Citation: Noémie JC, Chiche L (2015) Toward Precision Therapy in ANCA-Associated Vasculitides: More Transcriptomic Data is Needed in the Quest for Reliable Biomarkers. J Vasc 1:e103. doi: 10.4172/2471-9544.1000e103

Copyright: © 2015 Noemie JC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Vasculitis


The diagnosis of anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) is often made in a context of emergency, and relies on clinical presentation, positivity of ANCA antibodies and/or histological documentation [1]. The severity of residual organ damage, in particular chronic kidney disease (CKD), depends on the precocity of diagnosis, the efficacy of induction treatment, and on the prevention of AAV relapses [2,3]. Recently, although targeted therapy with rituximab have shown efficacy for the induction [4,5] and maintenance [6] of remission in AAV, residual organ damage and infectious complications are still penalizing patients. The identification of reliable biomarkers could help personalize the level and/or duration of immunosuppression (i.e., precision medicine).

Indeed, type and severity of organ involvement are heterogenous among patients, and ANCA positivity can be missing in patients with granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA) [7]. During follow-up, an increase in proteinuria or an impairment of renal function can result from chronic kidney disease progression, or from necrotizing pauci-immune crescentic glomerulonephritis, so that chronic renal lesions can be difficult to clinically discriminate from active vasculitis flare [8]. In such setting, renal biopsy is a valuable tool but remains an invasive procedure that cannot be repeated easily [9]. The follow-up of ANCA positivity and of anti-proteinase 3 (PR3) or anti-myeloperoxidase (MPO) antibodies titers is, to date, the most accurate biomarker available to evaluate disease activity and/or predict relapses [9]. Although several studies converge to show that severe flares were very unlikely in patients with negative ANCA [9-11], the clinical utility of ANCA follow-up to predict relapses is still debated [12], and no preemptive increase in immunosupresssion is currently recommended in patients showing new ANCA positivity or a rise in anti-PR3/anti-MPO titer [13]. These markers could be more predictive of relapse in patients with renal involvement of AAV (versus non-renal patients) [14], but this needs to be confirmed in validation cohorts.

So, while preventing AAV relapses using the minimally toxic immunosuppressive regimen is the goal of every clinicians taking care of patients with AAV, reliable non-invasive biomarkers are still needed in the quest for precision medicine. Surprisingly, especially compared to other autoimmune systemic diseases, and apart from genome-wide association studies (GWAS) [15], few data on AAV have been published from OMICs approaches. In GEO ( or ArrayExpress ( repositories, for instance, only few datasets of gene expression profiling of peripheral blood mononuclear cells (PBMC) [16], sorted lymphocytes [17], or microdissected glomeruli [18] are available in patients with AAV. To date, microarray data interpretation has been conducted with a knowledge-driven approach (Ingenuity Pathway Analysis or Gene Ontology) and has led to the identification of potential candidate biomarkers, namely ficolin-1 [16] and CC chemokine ligand [18]. The transcriptomic signature of purified CD8 T cells has been utilized to predict prognosis of patients with AAV or systemic lupus erythematosus (SLE) [17]. Although a 3 genes signature of CD8 T cells could accurately classify patients between those with good versus bad prognosis, pre-analytic constraint of cell sorting and purification prevented easy and reproducible use of those biomarkers in bedside clinical practice.

On the contrary, whole blood transcriptomic data, obtained from simple venipuncture, combined to data-driven analytic approaches could be of great interest in the identification of new biomarkers in AAV. A data-driven modular approach [19,20] has been used for the analysis of whole blood samples in the context of another systemic autoimmune disease, SLE, and has allowed to define more accurately the interferon signature in SLE [21], and to identify neutrophil signature as a biomarker of renal risk in SLE patients [22]. Such a strong neutrophil signature was also observed in AAV patients (Figure 1, unpublished data), which is not surprising given the central role of neutrophils in AAV pathogenesis [23]. The modular framework [19] has been constructed from a co-clustering algorithm on numerous samples. Modules are completely data-driven (as opposed to knowledge-driven constructed gene ensembles), and have been annotated a posteriori. Interestingly, the “neutrophil” module comprises the genes composing the “neutrophil” signature recently identified by the Immune Tolerance Network Research Group in whole blood of AAV patients as associated with disease activity and response to treatment [24]. The intensity of modular neutrophil signature is highly correlated to the upregulation of few representative genes, which can easily be measured by RT-PCR from whole blood samples as a “neutrophil score”, which makes this translatable to clinical practice (unpublished data).


Figure 1: Modular map of whole blood gene expression profile of 10 patients with severe active ANCA-associated vasculitis compared to match healthy controls. Modules up-regulated (in red) in AAV patients include M5.15, the module annotated “neutrophil” in the modular framework.

Overall, we propose that more whole blood transcriptomic data should be generated, made publically available [19,25,26], and analyzed through non-biased data-driven approaches, in different cohorts of patients with AAV from different ethnicities. This could allow the design of new bedside biomarkers to evaluate AAV activity, monitor response to treatment and assess individual risk of relapse at a given time, to reduce both organ damage and immunosuppression toxicity, and finally allow providing precision medicine to patients with AAV.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

Article Usage

  • Total views: 8108
  • [From(publication date):
    December-2015 - May 25, 2018]
  • Breakdown by view type
  • HTML page views : 8036
  • PDF downloads : 72

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7